SYNCHRONIZE-1 and SYNCHRONIZE-2 are global Phase III studies of survodutide (BI 456906) in people living with obesity and overweight without and with type 2 diabetes, respectively A third study, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma ®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback